AHF: 80 Organizations Denounce Gilead on Price Hikes Gutting ADAP

Core Points - 80 organizations have publicly denounced Gilead Sciences for significant price hikes that are negatively impacting the AIDS Drug Assistance Program (ADAP) [1] Group 1 - The price increases by Gilead are seen as detrimental to the accessibility of essential medications for individuals relying on ADAP [1] - The organizations argue that these price hikes undermine public health efforts and exacerbate health disparities among vulnerable populations [1] - Advocacy groups are calling for Gilead to reconsider its pricing strategy to ensure that life-saving treatments remain affordable [1]